Enovis Co. (NYSE:ENOV) Shares Acquired by First Eagle Investment Management LLC

First Eagle Investment Management LLC lifted its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 20.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 343,921 shares of the company's stock after acquiring an additional 59,525 shares during the period. First Eagle Investment Management LLC owned 0.60% of Enovis worth $15,091,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of ENOV. UMB Bank n.a. raised its holdings in Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after buying an additional 437 shares during the period. Pinnacle Bancorp Inc. raised its holdings in Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after buying an additional 300 shares during the period. FMR LLC raised its holdings in Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after buying an additional 484 shares during the period. XTX Topco Ltd purchased a new stake in Enovis in the 3rd quarter valued at about $217,000. Finally, Legacy Capital Wealth Partners LLC purchased a new stake in Enovis in the 4th quarter valued at about $228,000. Hedge funds and other institutional investors own 98.45% of the company's stock.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reduced their price objective on shares of Enovis from $65.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday, February 27th.

Remove Ads

Enovis Trading Up 1.0 %

NYSE:ENOV traded up $0.40 on Wednesday, reaching $39.41. 1,035,656 shares of the company's stock were exchanged, compared to its average volume of 666,419. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -17.99 and a beta of 2.05. The business has a fifty day moving average of $43.10 and a 200-day moving average of $43.62. Enovis Co. has a 52-week low of $35.14 and a 52-week high of $62.79.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. As a group, analysts expect that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.